Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)

Autor: Reijneveld, Jaap C., Machingura, Abigirl, Coens, Corneel, Taphoorn, Martin J.B., Taal, Walter, Clement, Paul M., Idbaih, Ahmed, de Vos, Filip Y.F., Klein, Martin, Wick, Wolfgang, Mulholland, Paul J., Lewis, Joanne, Golfinopoulos, Vassilis, Ghislain, Irina, Bottomley, Andrew, van den Bent, Martin J.
Zdroj: In European Journal of Cancer September 2023 190
Databáze: ScienceDirect
Externí odkaz: